Delhi HC restrains Zydus from launching Dabrafenib till patent expiry
Zydus undertakes not to commercially manufacture or launch Dabrafenib until Novartis' Indian patent expires in May 2029; statutory Bolar rights remain protected
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.
